Federal Circuit: Aggregated Financial Data From Different Products That Practice Different Patents Insufficient to Establish Domestic Industry

July 10, 2024

Reading Time : 2 min

In an appeal from the ITC, the Federal Circuit recently held that by presenting cumulative financial data across different products that practice various combinations of patents, appellant provided insufficient evidence for a court to evaluate domestic industry for any individual patent. And as a result, the court affirmed the ITC’s determination that the appellant failed to satisfy its burden to establish a domestic industry for any of its asserted patents.

The technology in this case related to stud finders. The appellant in this case asserted three patents each of which covered different features of its stud finder technology, including methods of calibration and features of the grips. In an effort to show domestic industry at the ITC, the appellant alleged that it met the domestic industry requirement based on investments in manufacturing, labor and capital, research and development, and the exploitation of its patents. As evidence of these investments, appellant provided financial data across 53 different products. Not all 53 products, however, practiced all three patents. Rather, only 14 of the 53 products practiced at least one claim of each asserted patent. The remaining products practiced only one or two of the asserted patents. But appellant’s domestic industry evidence aggregated the financial data for all products—it did not allocate the investments separately by product or patent.

At the ITC, the administrative law judge (ALJ) found that this evidence did not satisfy the economic prong for any of the asserted patents because it did not show a substantial or significant investment specific to any particular patent. On review, the ITC upheld the ALJ’s determination, explaining that instead of establishing domestic industry for products protected by each asserted patent, the complainant “aggregated its domestic industry products without regard for whether or which patents they practiced and then argued that a domestic industry in all of its products exists.” The aggregated information “failed to provide the Commission with an adequate basis to evaluate the investments and the significance of those investments with respect to each asserted patent.”

On appeal, appellant argued that Section 337 permits it to rely on investment data in the aggregate, so long as it ties expenditures to articles that practice some or all of the asserted patents. In other words, it need not show investments on a patent-by-patent basis.

The Federal Circuit rejected this argument, adopting the reasoning of the ALJ and ITC. As the court explained, a complainant must show “how much of its investment in each statutory category was attributable to each group of products” that practices an asserted patent. Thus, while it may be possible to aggregate data in certain circumstances, such as where all of the products practice all of the patents, such a method was inappropriate here where many of the products practiced fewer than all of the asserted patents. The court also confirmed its decision here does not preclude a party from grouping data for products that practice the same patents, so long as domestic industry can be determined for each patent.

Practice Tip: This case illustrates that, similar to damages apportionment, parties should give attention to ensuring that domestic industry evidence connects specific products to the specific patents they practice and does not depend on data for products that are not covered by the claims.

Zircon Corp. v. Int’l Trade Comm’n, 101 F.4d 817, 818 (Fed. Cir. 2024).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.